Navigation Links
Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Date:8/19/2007

Operating Loss Continues to Decline; Strategic Business Unit Realignment Completed; Clinical Update Provided for NicVAX Phase 2b Proof of Concept

Trial

BOCA RATON, Fla., Aug. 1 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced its second quarter financial results. The company recorded a net loss from continuing operations of $5.3 million, or $0.09 per share, for the quarter ended June 30, 2007, compared to $13.7 million, or $0.22 per share for the quarter ended July 1, 2006. Revenues for the second quarter of 2007 were $20.9 million compared to $20.4 million in 2006. Nabi-HB(R) [Hepatitis B Immune Globulin (Human)] revenues were $8.7 million during the second quarter of 2007 compared to $7.2 million during the second quarter of 2006.

For the six months ended June 30, 2007, the company's net loss from continuing operations was $16.0 million, or $0.26 per share, compared to $29.1 million, or $0.48 per share, for the six months ended July 1, 2006. Revenues for the year to date period were $44.6 million compared to $39.9 million in the first half of 2006.

Total cash used in operating activities was $18.9 million during the first half of 2007, a 44% reduction compared to $33.7 million in the first half of 2006. Excluding discontinued operations, cash used in operating activities was $13.1 million for the first half of 2007, a 53% reduction compared to $27.7 million for six months ended July 1, 2006. Cash, cash equivalents and marketable securities were $103.9 million at the end of the second quarter.

Nabi has completed the formation of two strategic business units (SBUs) -- Nabi Biologics and Nabi Pharmaceuticals -- to realign and
'/>"/>

SOURCE Nabi Biopharmaceuticals

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Sygnis Pharma AG announces date for presentation of clinical results
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... specific pathogens that cause serious infections and diseases, announced ... in the Company,s stock, the NYSE MKT (the "Exchange") ... practice. The Company stated that its policy is not ... Synthetic Biologics, Inc. Synthetic Biologics, Inc. (NYSE ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... diagnosisTAMPA, Fla., May 14 Moffitt Cancer ... have signed a license agreement on phospholipid ... been granted exclusive worldwide rights to Moffitt,s interests in ... maintenance fees, and royalties on sales. Moffitt and Frantz ...
... indicate statistically significant improvement in ACR20 responses over ... MEDX ) today announced that the ... active rheumatoid arthritis (RA) receiving methotrexate successfully met ... recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase ...
Cached Medicine Technology:Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 4
(Date:7/30/2014)... 2014 According to the American Cancer Society, ... in the United States in 2014. (1) NTC ... the mortgage and financial industry, has long been a proponent ... and the company has further demonstrated its commitment by participating ... & Tarpon Springs event to increase awareness and fundraising efforts ...
(Date:7/30/2014)... 30, 2014 A formal complaint ... Office against the maker of the dialysis products ... Medical Care defrauded the state, its residents, physicians ... dialysates, before they were recalled in 2012. There ... these products pending in the U.S. District Court, ...
(Date:7/30/2014)... July 29, 2014 (HealthDay News) -- A simple blood ... spina bifida, new research finds. The test would ... in a pregnant women,s red blood cells. The findings from ... -- could help doctors predict the risk of serious birth ... to the proper development of a growing fetus. In ...
(Date:7/30/2014)... 30, 2014 (HealthDay News) -- ,Middle-aged adults with a ... likely as others to develop severe memory problems later ... British researchers said their findings could help doctors identify ... from help for problem drinking. "We already know ... of current alcohol consumption -- that understanding is based ...
(Date:7/30/2014)... Loffler Companies, the leading business technology and services ... new production printing machines from Konica Minolta and Canon ... better. , With blazing 100 page-per-minute output speed in ... press raises the bar in digital productivity, saves space ... costs with simple operation and powerful in-line finishing. The ...
Breaking Medicine News(10 mins):Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 2Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 3Health News:NTC Takes Action Against Cancer With 5th Consecutive Relay For Life of Palm Harbor & Tarpon Springs, Raises Over $12,000 for Cancer Research 4Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 2Health News:Louisiana Attorney General Files Complaint Against GranuFlo Manufacturer, Baron and Budd Reports 3Health News:Blood Test Might Help Prevent Certain Birth Defects 2Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:Loffler Companies Introduces New Konica Minolta bizhub PRESS C1085/C1100 and Canon imagePRESS C800/C700 Devices 2Health News:Loffler Companies Introduces New Konica Minolta bizhub PRESS C1085/C1100 and Canon imagePRESS C800/C700 Devices 3
... Research Collaborative for Health, both in Ann Arbor, have ... disparities in access to liver transplantation among racial and ... of Liver Transplantation , a journal published by ... Study of Liver Diseases (AASLD). Organ allocation in ...
... Aug. 19 (HealthDay News)-- There were no smiles on the faces ... waiting on line for help from the Oregon Employment Department were ... lecture from a middle-aged woman, who leaned in close and whispered ... a lot of unhappy, stressed people here." At rows of ...
... ARBOR, Mich. A team of University of Michigan scientists ... lifespan of roundworms. Scientists who study aging have long known ... the goal is to find less drastic ways to achieve ... promising early evidence that scientists may succeed at finding targets ...
... Reporter , WEDNESDAY, Aug. 18 (HealthDay News) -- Quitting ... many headache-prone teens ease their suffering, new research suggests. ... between those three lifestyle factors and recurrent headaches among ... number of headaches teens get and forestall headaches for ...
... more than 1,800 years reduced the gastrointestinal side effects ... of the cancer treatment, Yale University researchers report. ... herbs, called PHY906, and is based on a herbal ... nausea, vomiting and diarrhea. The study, published August 18 ...
... transplantation (HCT) cures many blood diseases, two-thirds of long-term ... the procedure, according to a recent study published ... the American Society of Hematology. Overall, these patients were ... a severe or life-threatening health condition, such as cardiovascular, ...
Cached Medicine News:Health News:Hispanics and Asians less likely to receive liver transplants 2Health News:Hispanics and Asians less likely to receive liver transplants 3Health News:Jobless and Stressed but Holding Out Hope 2Health News:Discovery may aid search for anti-aging drugs 2Health News:Discovery may aid search for anti-aging drugs 3Health News:Bad Habits Tied to Recurrent Headaches in Teens 2Health News:Bad Habits Tied to Recurrent Headaches in Teens 3Health News:Chronic health conditions common for stem cell transplant survivors 2Health News:Chronic health conditions common for stem cell transplant survivors 3
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
... therapeutic fiberoptic bronchoscopes offers ... channel with a slim ... channel allows for improved ... of cytology brushes. The ...
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
Medicine Products: